BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Grünwald BT, Devisme A, Andrieux G, Vyas F, Aliar K, McCloskey CW, Macklin A, Jang GH, Denroche R, Romero JM, Bavi P, Bronsert P, Notta F, O'Kane G, Wilson J, Knox J, Tamblyn L, Udaskin M, Radulovich N, Fischer SE, Boerries M, Gallinger S, Kislinger T, Khokha R. Spatially confined sub-tumor microenvironments in pancreatic cancer. Cell 2021;184:5577-5592.e18. [PMID: 34644529 DOI: 10.1016/j.cell.2021.09.022] [Cited by in Crossref: 45] [Cited by in F6Publishing: 52] [Article Influence: 22.5] [Reference Citation Analysis]
Number Citing Articles
1 Sherman MH, Beatty GL. Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance. Annu Rev Pathol 2023;18:123-48. [PMID: 36130070 DOI: 10.1146/annurev-pathmechdis-031621-024600] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Wang Q, Wang J, Yan H, Li Z, Wang K, Kang F, Tian J, Zhao X, Yun SH. An ultra-small bispecific protein augments tumor penetration and treatment for pancreatic cancer. Eur J Nucl Med Mol Imaging 2023. [PMID: 36692541 DOI: 10.1007/s00259-023-06115-5] [Reference Citation Analysis]
3 Jiao Y, Geng R, Zhong Z, Ni S, Liu W, He Z, Gan S, Huang Q, Liu J, Bai J. A Hypoxia Molecular Signature-Based Prognostic Model for Endometrial Cancer Patients. Int J Mol Sci 2023;24:1675. [PMID: 36675190 DOI: 10.3390/ijms24021675] [Reference Citation Analysis]
4 Kiemen AL, Damanakis AI, Braxton AM, He J, Laheru D, Fishman EK, Chames P, Pérez CA, Wu P, Wirtz D, Wood LD, Hruban RH. Tissue clearing and 3D reconstruction of digitized, serially sectioned slides provide novel insights into pancreatic cancer. Med 2023. [DOI: 10.1016/j.medj.2022.11.009] [Reference Citation Analysis]
5 Drouillard D, Craig BT, Dwinell MB. Physiology of chemokines in the cancer microenvironment. Am J Physiol Cell Physiol 2023;324:C167-82. [PMID: 36317799 DOI: 10.1152/ajpcell.00151.2022] [Reference Citation Analysis]
6 Xie W, Cheng J, Hong Z, Cai W, Zhuo H, Hou J, Lin L, Wei X, Wang K, Chen X, Song Y, Wang Z, Cai J. Multi-Transcriptomic Analysis Reveals the Heterogeneity and Tumor-Promoting Role of SPP1/CD44-Mediated Intratumoral Crosstalk in Gastric Cancer. Cancers (Basel) 2022;15. [PMID: 36612160 DOI: 10.3390/cancers15010164] [Reference Citation Analysis]
7 Peiffer R, Boumahd Y, Gullo C, Crake R, Letellier E, Bellahcène A, Peulen O. Cancer-Associated Fibroblast Diversity Shapes Tumor Metabolism in Pancreatic Cancer. Cancers (Basel) 2022;15. [PMID: 36612058 DOI: 10.3390/cancers15010061] [Reference Citation Analysis]
8 Di Chiaro P, Nacci L, Brandini S, Polletti S, Donati B, Gualdrini F, Frige G, Mazzarella L, Ciarrocchi A, Zerbi A, Spaggiari P, Barozzi I, Diaferia GR, Natoli G. Coexisting morpho-biotypes unveil the regulatory bases of phenotypic plasticity in pancreatic ductal adenocarcinoma.. [DOI: 10.1101/2022.12.12.520054] [Reference Citation Analysis]
9 Seferbekova Z, Lomakin A, Yates LR, Gerstung M. Spatial biology of cancer evolution. Nat Rev Genet 2022. [DOI: 10.1038/s41576-022-00553-x] [Reference Citation Analysis]
10 Espinet E, Klein L, Puré E, Singh SK. Mechanisms of PDAC subtype heterogeneity and therapy response. Trends Cancer 2022;8:1060-71. [PMID: 36117109 DOI: 10.1016/j.trecan.2022.08.005] [Reference Citation Analysis]
11 Zhou Q, Chen D, Zhang J, Xiang J, Zhang T, Wang H, Zhang Y. Pancreatic ductal adenocarcinoma holds unique features to form an immunosuppressive microenvironment: a narrative review. Journal of Pancreatology 2022;5:174-185. [DOI: 10.1097/jp9.0000000000000109] [Reference Citation Analysis]
12 Neuzillet C, Nicolle R, Raffenne J, Tijeras-Raballand A, Brunel A, Astorgues-Xerri L, Vacher S, Arbateraz F, Fanjul M, Hilmi M, Samain R, Klein C, Perraud A, Rebours V, Mathonnet M, Bièche I, Kocher H, Cros J, Bousquet C. Periostin- and podoplanin-positive cancer-associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenocarcinoma. J Pathol 2022;258:408-25. [PMID: 36102377 DOI: 10.1002/path.6011] [Reference Citation Analysis]
13 Hingorani SR. Epithelial and stromal co-evolution and complicity in pancreatic cancer. Nat Rev Cancer 2022. [PMID: 36446904 DOI: 10.1038/s41568-022-00530-w] [Reference Citation Analysis]
14 Tong Y, Sun M, Chen L, Wang Y, Li Y, Li L, Zhang X, Cai Y, Qie J, Pang Y, Xu Z, Zhao J, Zhang X, Liu Y, Tian S, Qin Z, Feng J, Zhang F, Zhu J, Xu Y, Lou W, Ji Y, Zhao J, He F, Hou Y, Ding C. Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma. J Hematol Oncol 2022;15:168. [PMID: 36434634 DOI: 10.1186/s13045-022-01384-3] [Reference Citation Analysis]
15 Kast V, Nadernezhad A, Pette D, Gabrielyan A, Fusenig M, Honselmann KC, Stange DE, Werner C, Loessner D. A Tumor Microenvironment Model of Pancreatic Cancer to Elucidate Responses toward Immunotherapy. Adv Healthc Mater 2022;:e2201907. [PMID: 36417691 DOI: 10.1002/adhm.202201907] [Reference Citation Analysis]
16 Chiangjong W, Chutipongtanate S. EV-out or EV-in: Tackling cell-to-cell communication within the tumor microenvironment to enhance anti-tumor efficacy using extracellular vesicle-based therapeutic strategies. OpenNano 2022;8:100085. [DOI: 10.1016/j.onano.2022.100085] [Reference Citation Analysis]
17 Gonzalez-Molina J, Moyano-Galceran L, Single A, Gultekin O, Alsalhi S, Lehti K. Chemotherapy as a regulator of extracellular matrix-cell communication: Implications in therapy resistance. Semin Cancer Biol 2022;86:224-36. [PMID: 35331851 DOI: 10.1016/j.semcancer.2022.03.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
18 Bryce AS, Dreyer SB, Froeling FEM, Chang DK. Exploring the Biology of Cancer-Associated Fibroblasts in Pancreatic Cancer. Cancers 2022;14:5302. [DOI: 10.3390/cancers14215302] [Reference Citation Analysis]
19 Lautizi M, Baumbach J, Weichert W, Steiger K, List M, Pfarr N, Kacprowski T. The limits of molecular signatures for pancreatic ductal adenocarcinoma subtyping. NAR Cancer 2022;4:zcac030. [PMID: 36267208 DOI: 10.1093/narcan/zcac030] [Reference Citation Analysis]
20 Yu Q, Jiang M, Wu L. Spatial transcriptomics technology in cancer research. Front Oncol 2022;12:1019111. [DOI: 10.3389/fonc.2022.1019111] [Reference Citation Analysis]
21 Avraham-davidi I, Mages S, Klughammer J, Moriel N, Imada S, Hofree M, Murray E, Chen J, Pelka K, Mehta A, Boland GM, Delorey T, Caplan L, Dionne D, Tirosh I, Hacohen N, Chen F, Yilmaz O, Roper J, Rozenblatt-rosen O, Nitzan M, Regev A. Integrative single cell and spatial transcriptomics of colorectal cancer reveals multicellular functional units that support tumor progression.. [DOI: 10.1101/2022.10.02.508492] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 Creixell M, Kim H, Mohammadi F, Peyton SR, Meyer AS. Systems approaches to uncovering the contribution of environment-mediated drug resistance. Current Opinion in Solid State and Materials Science 2022;26:101005. [DOI: 10.1016/j.cossms.2022.101005] [Reference Citation Analysis]
23 Krieger TG, Sudy A, Schicktanz F, Tosti L, Liebig J, Konukiewitz B, Rouault M, Niesnerová A, Qian X, Weichert W, Eils R, Steiger K, Conrad C. Transcriptionally defined morphological subtypes of pancreatic ductal adenocarcinoma.. [DOI: 10.1101/2022.09.23.509133] [Reference Citation Analysis]
24 Liu T, Cheng S, Xu Q, Wang Z. Management of Advanced Pancreatic Cancer through Stromal Depletion and Immune Modulation. Medicina (Kaunas) 2022;58:1298. [PMID: 36143975 DOI: 10.3390/medicina58091298] [Reference Citation Analysis]
25 Aliar K, Waterhouse HR, Vyas F, Krebs N, Poulton E, Zhang B, Chan N, Bronsert P, Fischer SE, Gallinger S, Grünwald BT, Khokha R. Hourglass, a tool to mine bioimaging data, uncovers sex-disparities in the IL-6-associated T cell response in pancreatic tumors.. [DOI: 10.1101/2022.09.12.507618] [Reference Citation Analysis]
26 Yamamoto K, Iwadate D, Kato H, Nakai Y, Tateishi K, Fujishiro M. Targeting the Metabolic Rewiring in Pancreatic Cancer and Its Tumor Microenvironment. Cancers 2022;14:4351. [DOI: 10.3390/cancers14184351] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Rubin SJS, Sojwal RS, Gubatan J, Rogalla S. The Tumor Immune Microenvironment in Pancreatic Ductal Adenocarcinoma: Neither Hot nor Cold. Cancers 2022;14:4236. [DOI: 10.3390/cancers14174236] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Salinas-Miranda E, Healy GM, Grünwald B, Jain R, Deniffel D, O'Kane GM, Grant R, Wilson J, Knox J, Gallinger S, Fischer S, Khokha R, Haider MA. Correlation of transcriptional subtypes with a validated CT radiomics score in resectable pancreatic ductal adenocarcinoma. Eur Radiol 2022. [PMID: 36006427 DOI: 10.1007/s00330-022-09057-y] [Reference Citation Analysis]
29 Lou X, Zhao K, Xu J, Shuai L, Niu H, Cao Z, Wang J, Zhang Y. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma via M2 macrophage interactions: A bioinformatic analysis of the tumor microenvironment. Front Immunol 2022;13:950213. [DOI: 10.3389/fimmu.2022.950213] [Reference Citation Analysis]
30 Sunami Y, Chen Y, Trojanowicz B, Sommerer M, Hämmerle M, Eils R, Kleeff J. Single Cell Analysis of Cultivated Fibroblasts from Chronic Pancreatitis and Pancreatic Cancer Patients. Cells 2022;11:2583. [PMID: 36010660 DOI: 10.3390/cells11162583] [Reference Citation Analysis]
31 Song J, Ruze R, Chen Y, Xu R, Yin X, Wang C, Xu Q, Zhao Y. Construction of a novel model based on cell-in-cell-related genes and validation of KRT7 as a biomarker for predicting survival and immune microenvironment in pancreatic cancer. BMC Cancer 2022;22:894. [PMID: 35974300 DOI: 10.1186/s12885-022-09983-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Kaneko T, Zeng PYF, Liu X, Abdo R, Barrett JW, Zhang Q, Nichols AC, Li SS. Proteome and phosphoproteome signatures of recurrence for HPV(+) head and neck squamous cell carcinoma. Commun Med (Lond) 2022;2:95. [PMID: 35919862 DOI: 10.1038/s43856-022-00159-8] [Reference Citation Analysis]
33 Sugita K, Onishi I, Nakayama R, Ishibashi S, Ikeda M, Inoue M, Narita R, Oshima S, Shimizu K, Saito S, Sato S, Moriarity BS, Yamamoto K, Largaespada DA, Kitagawa M, Kurata M. Indirect CRISPR screening with photoconversion revealed key factors of drug resistance with cell–cell interactions.. [DOI: 10.1101/2022.07.15.500173] [Reference Citation Analysis]
34 Masugi Y. The Desmoplastic Stroma of Pancreatic Cancer: Multilayered Levels of Heterogeneity, Clinical Significance, and Therapeutic Opportunities. Cancers 2022;14:3293. [DOI: 10.3390/cancers14133293] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
35 Chen P, Dey P. Co-dependencies in the tumor immune microenvironment. Oncogene 2022;41:3821-9. [PMID: 35817840 DOI: 10.1038/s41388-022-02406-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Han S, Fu D, Tushoski GW, Meng L, Herremans KM, Riner AN, Geoge TJ, Huo Z, Hughes SJ. Single-cell profiling of microenvironment components by spatial localization in pancreatic ductal adenocarcinoma. Theranostics 2022;12:4980-92. [PMID: 35836806 DOI: 10.7150/thno.73222] [Reference Citation Analysis]
37 Harper MM, Lin M, Qasem SA, Patel RA, Cavnar MJ, Pandalai PK, Gao M, Kim J. Endogenous Pancreatic Cancer Cell PD-1 Activates MET and Induces Epithelial-Mesenchymal Transition to Promote Cancer Progression. Cancers 2022;14:3051. [DOI: 10.3390/cancers14133051] [Reference Citation Analysis]
38 Agostini A, Orlacchio A, Carbone C, Guerriero I. Understanding Tricky Cellular and Molecular Interactions in Pancreatic Tumor Microenvironment: New Food for Thought. Front Immunol 2022;13:876291. [DOI: 10.3389/fimmu.2022.876291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
39 Werba G, Weissinger D, Kawaler EA, Zhao E, Kalfakakou D, Dhara S, Oh G, Jing X, Beri N, Khanna L, Gonda T, Oberstein P, Hajdu C, Loomis C, Heguy A, Sherman MH, Lund AW, Welling TH, Dolgalev I, Tsirigos A, Simeone DM. Single-Cell RNA Sequencing Reveals the Effects of Chemotherapy on Human Pancreatic Adenocarcinoma and its Tumor Microenvironment.. [DOI: 10.1101/2022.05.24.493132] [Reference Citation Analysis]
40 Vahid MR, Brown EL, Steen CB, Kang M, Gentles AJ, Newman AM. Robust alignment of single-cell and spatial transcriptomes with CytoSPACE.. [DOI: 10.1101/2022.05.20.488356] [Reference Citation Analysis]
41 Albers JJ, Pelka K. Listening in on Multicellular Communication in Human Tissue Immunology. Front Immunol 2022;13:884185. [DOI: 10.3389/fimmu.2022.884185] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Casamitjana J, Espinet E, Rovira M. Pancreatic Organoids for Regenerative Medicine and Cancer Research. Front Cell Dev Biol 2022;10:886153. [DOI: 10.3389/fcell.2022.886153] [Reference Citation Analysis]
43 Shang L, Ye F, Li M, Zhao Y. Spatial confinement toward creating artificial living systems. Chem Soc Rev 2022. [PMID: 35502858 DOI: 10.1039/d1cs01025e] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Liu K, Cui J, Zhan Y, Ouyang Q, Lu Q, Yang D, Li X, Yin J. Reprogramming the tumor microenvironment by genome editing for precision cancer therapy. Mol Cancer 2022;21. [DOI: 10.1186/s12943-022-01561-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
45 Huang X, Zhang G, Liang T. Subtyping for pancreatic cancer precision therapy. Trends in Pharmacological Sciences 2022. [DOI: 10.1016/j.tips.2022.03.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Sandhya S, Hogenson TL, Fernandez-Zapico ME. Patient-derived organoids, creating a new window of opportunities for pancreatic cancer patients. EMBO Mol Med 2022;:e15707. [PMID: 35285156 DOI: 10.15252/emmm.202215707] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 M A M, Kim JY, Pan CH, Kim E. The impact of the spatial heterogeneity of resistant cells and fibroblasts on treatment response. PLoS Comput Biol 2022;18:e1009919. [PMID: 35263336 DOI: 10.1371/journal.pcbi.1009919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Melzer MK, Roger E, Kleger A. State-matched organoid models to fight pancreatic cancer. Trends in Cancer 2022. [DOI: 10.1016/j.trecan.2022.03.003] [Reference Citation Analysis]
49 Okuda R, Gjeta B, Popovic D, Maynard A, Yu Q, He Z, Santel M, Seimiya M, Morinaga S, Miyagi Y, Yamaguchi T, Ueno Y, Taniguichi H, Treutlein B, Camp JG. Reconstructing cell interactions and state trajectories in pancreatic cancer stromal tumoroids.. [DOI: 10.1101/2022.02.14.480334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Poon S, Ailles LE. Modeling the Role of Cancer-Associated Fibroblasts in Tumor Cell Invasion. Cancers (Basel) 2022;14:962. [PMID: 35205707 DOI: 10.3390/cancers14040962] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
51 Peschke K, Jakubowsky H, Schäfer A, Maurer C, Lange S, Orben F, Bernad R, Harder FN, Eiber M, Öllinger R, Steiger K, Schlitter M, Weichert W, Mayr U, Phillip V, Schlag C, Schmid RM, Braren RF, Kong B, Demir IE, Friess H, Rad R, Saur D, Schneider G, Reichert M. Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. EMBO Mol Med 2022;:e14876. [PMID: 35119792 DOI: 10.15252/emmm.202114876] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
52 Mäkinen L, Vähä-koskela M, Juusola M, Mustonen H, Wennerberg K, Hagström J, Puolakkainen P, Seppänen H. Pancreatic Cancer Organoids in the Field of Precision Medicine: A Review of Literature and Experience on Drug Sensitivity Testing with Multiple Readouts and Synergy Scoring. Cancers 2022;14:525. [DOI: 10.3390/cancers14030525] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Combes AJ, Samad B, Tsui J, Chew NW, Yan P, Reeder GC, Kushnoor D, Shen A, Davidson B, Barczak AJ, Adkisson M, Edwards A, Naser M, Barry KC, Courau T, Hammoudi T, Argüello RJ, Rao AA, Olshen AB, Cai C, Zhan J, Davis KC, Kelley RK, Chapman JS, Atreya CE, Patel A, Daud AI, Ha P, Diaz AA, Kratz JR, Collisson EA, Fragiadakis GK, Erle DJ, Boissonnas A, Asthana S, Chan V, Krummel MF; Immunoprofiler Consortium. Discovering dominant tumor immune archetypes in a pan-cancer census. Cell 2022;185:184-203.e19. [PMID: 34963056 DOI: 10.1016/j.cell.2021.12.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 24.0] [Reference Citation Analysis]
54 Halbrook CJ, Thurston G, Boyer S, Anaraki C, Jiménez JA, McCarthy A, Steele NG, Kerk SA, Hong HS, Lin L, Law FV, Felton C, Scipioni L, Sajjakulnukit P, Andren A, Beutel AK, Singh R, Nelson BS, Van Den Bergh F, Krall AS, Mullen PJ, Zhang L, Batra S, Morton JP, Stanger BZ, Christofk HR, Digman MA, Beard DA, Viale A, Zhang J, Crawford HC, Pasca di Magliano M, Jorgensen C, Lyssiotis CA. Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells. Nat Cancer 2022;3:1386-403. [PMID: 36411320 DOI: 10.1038/s43018-022-00463-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Cao S, Wang JR, Ji S, Yang P, Dai Y, Guo S, Montierth MD, Shen JP, Zhao X, Chen J, Lee JJ, Guerrero PA, Spetsieris N, Engedal N, Taavitsainen S, Yu K, Livingstone J, Bhandari V, Hubert SM, Daw NC, Futreal PA, Efstathiou E, Lim B, Viale A, Zhang J, Nykter M, Czerniak BA, Brown PH, Swanton C, Msaouel P, Maitra A, Kopetz S, Campbell P, Speed TP, Boutros PC, Zhu H, Urbanucci A, Demeulemeester J, Van Loo P, Wang W. Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. Nat Biotechnol 2022;40:1624-33. [PMID: 35697807 DOI: 10.1038/s41587-022-01342-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
56 Vaish U, Jain T, Are AC, Dudeja V. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma: An Update on Heterogeneity and Therapeutic Targeting. Int J Mol Sci 2021;22:13408. [PMID: 34948209 DOI: 10.3390/ijms222413408] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
57 Raghavan S, Winter PS, Navia AW, Williams HL, DenAdel A, Lowder KE, Galvez-Reyes J, Kalekar RL, Mulugeta N, Kapner KS, Raghavan MS, Borah AA, Liu N, Väyrynen SA, Costa AD, Ng RWS, Wang J, Hill EK, Ragon DY, Brais LK, Jaeger AM, Spurr LF, Li YY, Cherniack AD, Booker MA, Cohen EF, Tolstorukov MY, Wakiro I, Rotem A, Johnson BE, McFarland JM, Sicinska ET, Jacks TE, Sullivan RJ, Shapiro GI, Clancy TE, Perez K, Rubinson DA, Ng K, Cleary JM, Crawford L, Manalis SR, Nowak JA, Wolpin BM, Hahn WC, Aguirre AJ, Shalek AK. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell 2021;184:6119-6137.e26. [PMID: 34890551 DOI: 10.1016/j.cell.2021.11.017] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 32.5] [Reference Citation Analysis]